التفاصيل البيبلوغرافية
| العنوان: |
Tumefactive demyelinating lesions during etanercept treatment requiring decompressive hemicraniectomy. |
| المؤلفون: |
Cereda, CW1, Zecca, C1, Mazzucchelli, L2, Valci, L3, Staedler, C1, Bassetti, CL4, Gobbi, C1 |
| المصدر: |
Multiple Sclerosis Journal. May2013, Vol. 19 Issue 6, p820-823. 4p. 1 Color Photograph. |
| مصطلحات موضوعية: |
*TUMOR necrosis factors, *AUTOIMMUNE diseases, *MAGNETIC resonance imaging, *ETANERCEPT, *TISSUE wounds, *DEMYELINATION |
| مستخلص: |
Tumor necrosis factor alpha (TNF-α) is a pro-inflammatory and immunoregulatory cytokine involved in the pathogenesis of several autoimmune disorders. Etanercept, a TNF-α antagonist (anti-TNF-α) acting as a soluble TNF-α receptor, has been associated with neurological demyelinating disorders. This paper aims to report an unusual case showing tumefactive central nervous system (CNS) inflammatory demyelination in a patient in the course of TNF -α antagonist therapy, requiring decompressive hemicraniectomy. This report is based on magnetic resonance imaging (MRI) findings and histology. A biopsy confirmed the inflammatory demyelinating nature of the lesions. The clinical presentation is unusual due to the severity of the disease process, requiring decompressive hemicraniotomy with a clinically favorable outcome. [ABSTRACT FROM AUTHOR] |
| قاعدة البيانات: |
Academic Search Index |
